NHS NEL
Demonstration Formulary
Demonstration Formulary
6 Endocrine system
06-06-01 Calcitonin and parathyroid hormone
| Calcitonin (salmon) / Salcatonin |
|
Formulary
|
Injection Nasal spray For hospital use only |
 NICE TA161: Osteoporosis - secondary prevention (including strontium ranelate) |
|
Links
- DVLA guidance
- ESCA: Ibandronic acid 50mg-Sandwell only
- ESCA: Sodium clodronate-Sandwell only
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- NICE Guidance on prescribing
- NICE NG28: Type 2 diabetes in adults: management
- NICE TA 791: Romosozumab for treating severe osteoporosis
- NICE TA160: Osteoporosis - Primary Prevention
- NICE TA161: Osteoporosis - secondary prevention (including strontium ranelate)
- NICE TA161: Osteoporosis - secondary prevention (including Teriparatide)
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
NOGG Osteoporosis - information for patients- NOGG Osteoporosis Clinical Guideline Executive Summary
- NOGG Pocket Guide for Heathcare Professionals - Osteoporosis
- TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)